Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CV Therapeutics has reported that Ranexa significantly reduced the risk of recurrent ischemia, worsening angina and intensification of antianginal therapy, in angina patients in the Merlin-Timi 36 study.
Subscribe to our email newsletter
Additionally, Ranexa has significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset of 1mm ST segment depression (p=0.002), a signal of ischemia, in these Merlin-Timi 36 angina patients.
David Morrow, lead investigator of the Merlin-Timi 36 study, said: “This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina.”